Prebiotic UG1601 mitigates constipation-related events in association with gut microbiota: A randomized placebo-controlled intervention study  

作　　者：Jae Ryang Chu Saem-Yi Kang Sung-Eun Kim Sol-Ji Lee Young-Chul Lee Mi-Kyung Sung 

机构地区：[1]Department of Food and Nutrition,Sookmyung Women’s University,Seoul 04310,South Korea [2]Unigen,Inc.,Cheonan 31257,South Korea

出　　处：《World Journal of Gastroenterology》2019年第40期6129-6144,共16页世界胃肠病学杂志（英文版）

基　　金：Supported by the Unigen,Inc.;the Mid-Career Research Program of the National Research Foundation of Korea,No.2015R1A2A2A01004607;the Basic Science Research Program of the National Research Foundation of Korea,No.NRF-2016R1A6A3A11934151

摘　　要：BACKGROUND Constipation is a common functional gastrointestinal disorder and its etiology is multifactorial.Growing evidence suggests that intestinal dysbiosis is associated with the development of constipation.Prebiotics are subjected to bacterial fermentation in the gut to produce short-chain fatty acids(SCFAs),which can help relieve constipation symptoms.The prebiotic UG1601 consists of inulin,lactitol,and aloe vera gel,which are known laxatives,but randomized,controlled clinical trials that examine the effects of this supplement on gut microbiota composition are lacking.AIM To assess the efficacy of the prebiotic UG1601 in suppressing constipation-related adverse events in subjects with mild constipation.METHODS Adults with a stool frequency of less than thrice a week were randomized to receive either prebiotics or a placebo supplement for 4 wk.All participants provided their fecal and blood samples at baseline and at the end of intervention.Gastrointestinal symptoms and stool frequency were evaluated.The concentrations of serum endotoxemia markers and fecal SCFAs were determined.The relative abundance of SCFA-producing bacteria and the gut microbial community in the responders and non-responders in the prebiotics supplementation group were evaluated.RESULTS There were no significant differences in gastrointestinal symptoms between groups,although the prebiotic group showed greater symptom improvement.However,after prebiotic usage,serum cluster of differentiation(CD)14 and lipopolysaccharide(LPS)concentrations were significantly decreased(CD14,P=0.012;LPS,P<0.001).The change in LPS concentration was significantly larger in the prebiotic group than in the placebo group(P<0.001).Fecal SCFAs concentrations did not differ between groups,while the relative abundance of Roseburia hominis,a major butyrate producer,was significantly increased in the prebiotic group(P=0.045).The abundances of the phylum Firmicutes and the family Lachnospiraceae(phylum Firmicutes,class Clostridia)(P=0.009)were decreased in the respondeBACKGROUND Constipation is a common functional gastrointestinal disorder and its etiology is multifactorial. Growing evidence suggests that intestinal dysbiosis is associated with the development of constipation. Prebiotics are subjected to bacterial fermentation in the gut to produce short-chain fatty acids(SCFAs), which can help relieve constipation symptoms. The prebiotic UG1601 consists of inulin,lactitol, and aloe vera gel, which are known laxatives, but randomized, controlled clinical trials that examine the effects of this supplement on gut microbiota composition are lacking.AIM To assess the efficacy of the prebiotic UG1601 in suppressing constipation-related adverse events in subjects with mild constipation.METHODS Adults with a stool frequency of less than thrice a week were randomized to receive either prebiotics or a placebo supplement for 4 wk. All participants provided their fecal and blood samples at baseline and at the end of intervention.Gastrointestinal symptoms and stool frequency were evaluated. The concentrations of serum endotoxemia markers and fecal SCFAs were determined.The relative abundance of SCFA-producing bacteria and the gut microbial community in the responders and non-responders in the prebiotics supplementation group were evaluated.RESULTS There were no significant differences in gastrointestinal symptoms between groups, although the prebiotic group showed greater symptom improvement.However, after prebiotic usage, serum cluster of differentiation(CD) 14 and lipopolysaccharide(LPS) concentrations were significantly decreased(CD14, P =0.012; LPS, P < 0.001). The change in LPS concentration was significantly larger in the prebiotic group than in the placebo group(P < 0.001). Fecal SCFAs concentrations did not differ between groups, while the relative abundance of Roseburia hominis, a major butyrate producer, was significantly increased in the prebiotic group(P = 0.045). The abundances of the phylum Firmicutes and the family Lachnospiraceae(phylum Firmicutes, class Clostridia)(P = 0.

关 键 词：PREBIOTICS CONSTIPATION Gut MICROBIOTA ENDOTOXEMIA Short-chain FATTY acids 

分 类 号：R57[医药卫生—消化系统]